Pooled Analysis of Patients With Early-stage Breast Cancer Treated With Adjuvant Dose-dense Sequential Chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study.

Overall survival

OS is defined as the time from diagnosis or surgery to death from any cause. Patients alive at the last follow-up are censored. Analyses are performed using pooled individual patient data from studies conducted by the Hellenic Cooperative Oncology Group (HeCOG)

Time frame: From date of diagnosis or surgery to death from any cause. Patients alive at last follow-up are censored at that date

Treatment-related toxicity

Τreatment-related toxicities observed during adjuvant or neoadjuvant therapy in patients with early breast cancer will be analyzed using pooled individual patient data from seven clinical studies conducted by the Hellenic Cooperative Oncology Group (HeCOG). This includes hematologic and non-hematologic adverse events reported during therapy.

Time frame: From the first dose of treatment until 5 years after the last dose

Overall survival

Overall survival was defined as the time from the date of diagnosis to the date of death. Patients are censored at last follow-up

Time frame: From the date of diagnosis to the date of death